Swiss CDMOs and CROs experience rapid growth as global sponsors seek specialized manufacturing and decentralized trials

Switzerland’s contract development and manufacturing organisations (CDMOs) and contract research organisations (CROs) are entering a new boom cycle, driven by rising global demand for specialised manufacturing, human‑relevant preclinical models and increasingly complex clinical trials.

The sector is seeing notable consolidation. Samsung Biologics launched a CHF 1.46 billion all‑cash tender offer for peptide CDMO PolyPeptide Group, aiming to tap the fast‑growing obesity and metabolic drug market. Around the same time, Swiss‑owned Corden Pharma completed its purchase of AmbioPharm to boost peptide production capabilities.

Industry experts say sponsors are gravitating toward Swiss hubs for the country’s strong talent pool, innovative capacity and regulatory stability. This mix of expertise and infrastructure is encouraging service providers to scale, diversify and position Switzerland as a preferred destination for next‑generation drug development.